Sarah Chen
The Data Hawk
Hims & Hers Faces FTC Lawsuit: Implications for Telehealth Investors
Hims & Hers faces regulatory scrutiny, prompting a closer look at its telehealth business model and …
Curaleaf's Hostile Bid for Aurora Cannabis: Implications for North American Cannabis Investors
Curaleaf's $4/share bid for Aurora Cannabis signals major changes in the cannabis sector, impacting …
Raytheon's $22.9 Billion Contract: A Game Changer for Defense Investors
Raytheon's $22.9 billion contract signals a shift in defense spending amidst rising geopolitical ten…
TTM Technologies Acquires Epiq Solutions: A Strategic Move in Defense Electronics
TTM Technologies' $1.1 billion acquisition of Epiq Solutions signals a strong move in the defense el…
Intel and Nvidia Lead AI Surge: Insights for Tech Investors
Intel and Nvidia drive market activity as inflation moderates, boosting tech sectors. Key insights f…
Brookfield and La Caisse's Boralex Acquisition: A New Era for Canadian Renewable Energy
Brookfield and La Caisse's acquisition of Boralex signals a significant move in Canada's renewable e…
Lantheus Holdings' Tauklarify Approval: A Game Changer for Alzheimer's Imaging
Lantheus Holdings receives FDA approval for Tauklarify, enhancing its position in the Alzheimer's di…
Capricor Therapeutics: A High-Stakes Bet on FDA Decision
Capricor Therapeutics' stock surged 67% after-hours amidst anticipation of an FDA decision on derami…
Outlook Therapeutics Faces Investor Backlash Post-FDA Approval: A Cautionary Tale
Outlook Therapeutics (OTLK) faces investor backlash as capital raise impacts share prices despite FD…
Rocket Lab's Strategic Move: Clearing Regulatory Hurdles in the Iridium Acquisition
Rocket Lab's acquisition of Iridium marks a pivotal shift towards integrated space infrastructure, i…
Neurocrine Biosciences (NBIX) Faces Regulatory Scrutiny After Safety Concerns: What Investors Should Know
Neurocrine Biosciences (NBIX) faces scrutiny from regulators following safety alarms, including seve…
Definium Therapeutics Soars on Trial Success: What This Means for Investors
Definium Therapeutics stock surged 20% following positive Phase 3 trial results, signaling a signifi…
AbCellera's ABCL635: Positive Data Fuels Market Optimism and Analyst Upgrades
AbCellera Biologics' positive Phase 2 results for ABCL635 have led to increased analyst confidence a…
Thoma Bravo's C$650M Acquisition of Kneat: What It Means for the Canadian Tech Landscape
Thoma Bravo's C$650M acquisition of Kneat signals a pivotal shift in the Canadian tech market amidst…
Jazz Pharmaceuticals Expands Pipeline with $1.32 Billion Acquisition of Actio Biosciences
Jazz Pharmaceuticals announces $1.32 billion acquisition of Actio Biosciences, enhancing its rare di…
Amneal Pharmaceuticals' Strategic Move: Acquisition of Kashiv BioSciences
Amneal's acquisition of Kashiv BioSciences positions it as a leader in the biosimilars market, indic…
Potential New Revenue Stream: AbbVie’s BOTOX Cosmetic Application Progress and Market Implications
Exploring the implications of FDA's acceptance of BOTOX for masseter muscle prominence on AbbVie's f…
NRx Pharmaceuticals Moves Closer to Launching Preservative-Free Ketamine
NRx Pharmaceuticals' ANDA for preservative-free ketamine passes FDA first-cycle review, signaling si…
US Jobs Report Shock: What the -23K Non-Farm Payrolls Mean for Markets
The unexpected -23,000 non-farm payrolls in July raises questions about market stability and economi…
Tarsus Pharmaceuticals Expands Eye Care Pipeline with Alkeus Acquisition
Tarsus Pharmaceuticals strengthens its eye care portfolio by acquiring Alkeus Pharmaceuticals, focus…